Corinne Savill
Corporate Officer/Principal bei CULLINAN THERAPEUTICS, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Corinne Savill is currently the Chief Business Officer at Cullinan Oncology, Inc. She previously worked as the CEO of Imutran Ltd.
from 1995 to 2001, and as the Global Head of Business Development & Licensing at Novartis Pharma AG from 2002 to 2017.
She also briefly served as a Director at Cantargia AB in 2018.
Dr. Savill has an undergraduate degree from The University of Manchester and a doctorate from Middlesex School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.02.2024 | 203 490 ( 0,47% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Corinne Savill
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Corporate Officer/Principal | 01.02.2017 |
Ehemalige bekannte Positionen von Corinne Savill
| Unternehmen | Position | Ende |
|---|---|---|
| CANTARGIA AB | Director/Board Member | 21.05.2018 |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.02.2017 |
| Imutran Ltd. | Chief Executive Officer | 01.01.2001 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Corinne Savill
| The University of Manchester | Undergraduate Degree |
| Middlesex School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CANTARGIA AB | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
| Imutran Ltd. |
